SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

Avalo Therapeutics is generating significant investor interest driven by high trading volumes, active momentum in its clinical-stage pipeline, and multiple analyst endorsements from firms like Guggenheim and HC Wainwright. Community discussion is focused on the high-stakes Phase 2 LOTUS trial readout expected in 2026 and ongoing debates regarding the company's financial risk profile versus the potential upside of its immunology platform.

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costco is currently trending as investors monitor its resilience amid macroeconomic volatility and ongoing debates surrounding the impact of potential tariff refunds on retail pricing. The community remains focused on Costco's defensive strengths, with frequent discussions centered on its robust membership renewal rates, traffic growth, and valuation relative to the broader consumer staples sector.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is currently a major focal point for traders due to its recent surge in social media volume and discussion surrounding its post-quantum security features. Community members remain polarized, with many debating the impact of institutional-grade infrastructure upgrades and potential regulatory shifts while long-term holders focus on accumulation during significant price volatility.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as the community speculates on a major upcoming partnership announcement, with many pointing to a connection with Stellar or a potential collaboration with Ripple/XRP at an upcoming industry event. Investors are actively debating the project's long-term utility in global payroll and real-world adoption, balancing high-conviction sentiment against skepticism regarding its price performance and market volatility.

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF is capturing investor attention as they rotate toward defensive, value-oriented positions amidst broader market volatility. The community is actively debating the fund's resilience, with many investors maintaining a long-term 'buy and hold' strategy despite recent stagnant performance, while others monitor the ETF's sector diversification and dividend growth potential as a reliable hedge.

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.

Clene Inc

Clene Inc. is trending as the community eagerly awaits definitive biomarker data and regulatory updates regarding an accelerated approval pathway for its ALS candidate, CNM-Au8. Investors are closely monitoring upcoming conference presentations and regulatory milestones, balancing high-conviction long-term sentiment against volatility driven by short interest and recent insider selling activity.

BtcUSD is a completely decentralized stablecoin issued and managed by BTCFi, a platform where users can deposit Bitcoin of various formats to use as collaterals. BtcUSD offers Bitcoin holders the opportunity to generate additional yields with their Bitcoin positions through DeFi usage.

Bitcoin USD (BTCFi)

Bitcoin is experiencing heightened volatility and intense community debate as it tests critical support levels around 60k-65k, with traders closely monitoring technical formations like bear flags and head-and-shoulders patterns. While some bulls are looking for a reclaim of key resistance zones to trigger a long-term uptrend, many participants remain cautious, pointing to equity market weakness and potential liquidity risks that could lead to further downside tests.

The Internet Computer is a decentralized cloud blockchain designed to run applications, websites, and backend systems fully on-chain. Its architecture provides robust security, resilience, and built-in multi-chain support.  A key focus of the network is enabling a “self-writing cloud,” where AI tools allow users generate applications through natural-language instructions.  Developers and users can experiment with the platform using AI app-generation tools like caffeine.ai or by writing serverless code directly through online IDEs such as icp.ninja.  The ICP token is used to pay for computation (through a burn-based model) and to participate in network governance through staking.

Internet Computer

Internet Computer (ICP) is currently a focal point for the community due to major structural updates like Mission 70aimed at reducing token inflationand increasing adoption through sovereign subnets in regions like Switzerland and Pakistan. While some users remain skeptical due to historical volatility and the project's long-term performance, many community members are highlighting the real-world utility of platforms like Caffeine.ai and the growing number of canisters as indicators that the network's fundamentals are strengthening for a future recovery.

Provides investment banking, securities and asset management services

Goldman Sachs Group, Inc.

Goldman Sachs is capturing significant attention as the firm integrates advanced AI models to automate compliance roles, while simultaneously navigating heightened market scrutiny over its past ties to Jeffrey Epstein and recent leadership resignations. The stock is experiencing intense volatility as investors weigh these corporate headwinds against the firm's strategic expansion into private credit and asset management.

Babcock & Wilcox Enterprises, Inc. engages in the provision of fossil and renewable power generation and environmental equipment. It operates through the B&W segment. The company was founded by George H. Babcock, Stephen Wilcox, Jr., and Joseph P. Manton in 1856 and is headquartered in Akron, OH.

Babcock & Wilcox Enterprises Inc

Babcock & Wilcox (BW) is experiencing significant momentum following a major $2.4 billion power infrastructure contract, with community discussions largely focused on its role in providing essential energy solutions for AI data centers. The stock is a primary focal point for investors tracking related holdings like B. Riley (RILY) and Applied Digital (APLD), as participants debate the impact of institutional backing and the potential for a long-term valuation re-rating.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>IMUX shares have consistently traded above $1 since February 27.</li><li>The company appointed Jon Congleton, CEO of Mineralys Therapeutics, to its board of directors on Tuesday.</li><li>It recently closed a private placement of up to $400 million to support late-stage trials for the treatment of multiple sclerosis.</li></ul>Shares of Immunic, Inc (IMUX) gained around 7% on Wednesday after the company said it had regained compliance with Nasdaq’s listing rules on March 26.The firm regained compliance after the stock closed at or above $1 for at least 20 consecutive business days. The update removes concerns about a potential delisting from the Nasdaq Capital Market.<a href="https://stocktwits.com/symbol/IMUX">IMUX shares</a> have consistently&nbsp;traded above $1 since February 27.On Tuesday, the company appointed Jon Congleton, CEO of Mineralys Therapeutics, to its board of directors.&nbsp;<h2 class="st-heading-2">Immunic Secures Patent And Raises $400 Million</h2>Last month, the European Patent Office granted Immunic a key patent covering dosing regimens for its lead drug, Vidofludimus Calcium, to treat patients with&nbsp;multiple sclerosis. The protection is expected to last until 2038, with a potential extension to 2043.&nbsp;The patent broadly covers multiple forms of the drug, ensuring strong exclusivity across Europe and building on earlier approval from the United States Patent and Trademark Office.The company also closed a private placement of up to $400 million, led by BVF Partners. Immunic secured $200 million upfront, with additional funding tied to future warrants. The company said the funds will support late-stage trials for multiple sclerosis, aimed at helping slow disease progression.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits remained in the ‘bearish’ zone over the past 24 hours.One user highlighted the potential for a reverse share split.<stembedurl>https://stocktwits.com/ccledez/message/649165039</stembedurl>Another user was bullish about Congleton’s appointment.<stembedurl>https://stocktwits.com/Mvvh1987/message/649022575</stembedurl>Year-to-date, the stock has gained more than 113%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

IMUX Stock Jumps 6% Pre-Market Today – Here’s The Latest Update On Its Compliance With Nasdaq Listing Rules 

Shares of Immunic, Inc (IMUX) gained around 6% in pre-market trading on Wednesday after the company said it had regained compliance with Nasdaq’s listing rules on March 26.

Equity

The company regained compliance after the stock closed at or above $1 for at least 20 consecutive business days.

Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement

Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement PR Newswire NEW YORK, April 1, 2026 NEW YORK, April 1, 2026 /PRNewswire/ -- Immunic, Inc.(Nasdaq: IMUX),a late-stage biotechnology company pioneering the...

Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton

Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton Immunic Strengthens Its Board of Directors with the Appointment of Seasoned...

Immunic (NASDAQ:IMUX) Earns Buy Rating from Analysts at Guggenheim

Guggenheim initiated coverage on shares of Immunic in a research report on Tuesday. They issued a "buy" rating and a $7.00 price objective for the company...

Immunic, Inc. (NASDAQ:IMUX) Given Average Recommendation of "Buy" by Brokerages

Immunic, Inc. (NASDAQ:IMUX - Get Free Report) has been assigned an average rating of "Buy" from the eight ratings firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, five have given a buy recommendation and...

Immunic Conference: Transformative 2026 Ahead With Pivotal MS Data Due Late Year, NDA Next

Immunic (NASDAQ:IMUX) executives outlined what they described as a transformative 2026, with pivotal data expected late in the year for the company's lead multiple sclerosis (MS) candidate...

Immunic Details Vidofludimus Calcium MS Strategy, Phase III Timeline at Leerink Conference

Immunic (NASDAQ:IMUX) executives outlined their multiple sclerosis (MS) development strategy and commercial thinking for vidofludimus calcium during a session at the Leerink Partners Global...

Short Interest in Immunic, Inc. (NASDAQ:IMUX) Rises By 14.5%

Immunic, Inc. (NASDAQ:IMUX - Get Free Report) saw a large growth in short interest during the month of February. As of February 27th, there was short interest totaling 7,579,660 shares, a growth of...

Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium

Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for...

Immunic to Participate in Investor Conferences in March

Immunic to Participate in Investor Conferences in March Immunic to Participate in Investor Conferences in March PR Newswire NEW YORK, March 3, 2026 NEW YORK, March 3, 2026 /PRNewswire/ -- Immunic...

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on multiple sclerosis, celiac disease and other neurologic and gastrointestinal disorders. The firm's products include IMU-838, IMU-856, and IMU-381. The company was founded in 2016 and is headquartered in New York, NY.

Immunic Inc

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

IMUX
Immunic Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest IMUX News

IMUXImmunic Inc